

19. Pharmaceutical composition which comprises, as the active component, a polypeptide according to claim 13 where appropriate together with other active components and pharmaceutically customary adjuvants, additives or excipients.

20. A method for preparing an agent for the diagnosis or for the treatment or prevention of AITP comprising:

providing a polypeptide according to claim 13, and combining with a pharmaceutically acceptable carrier, thereby preparing an agent for the diagnosis or for the treatment or prevention of AITP.

21. A method for preparing an agent for exerting an effect on the binding of fibrinogen to blood platelets providing a polypeptide according to claim 13, and combining with a pharmaceutically acceptable carrier, thereby preparing an agent for exerting an effect on the binding of fibrinogen to blood platelets.

Please add new claims 26-29 as follows:

26. The polypeptide of claim 13, further comprising a second polypeptide subunit encoded by a nucleic acid which encodes a light chain, which is able to bind to GPIIb/IIIa, of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR3 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

A T W D D G L N G P V, 37 56 101

(b) a nucleotide sequence which encodes the amino acid sequence

A A W D D S L N G W V, and 38 57 102

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b), with the proviso that when the nucleic acid encompasses a nucleotide sequence according to (b), it does not simultaneously comprise nucleotide sequences which encode the amino acid sequences SGSSSNIGSNTVN and SNNQRPS, and when the nucleic acid comprises a nucleotide sequence according to (c), it does not simultaneously comprise nucleotide

sequences which encode the amino acid sequences SGSSSNIGSNTVN and RNNQRPS.

27. Pharmaceutical composition which comprises, as the active component, a polypeptide according to claim 26 where appropriate together with other active components and pharmaceutically customary adjuvants, additives or excipients.

28. A method for preparing an agent for the diagnosis or for the treatment or prevention of AITP comprising:

providing a polypeptide according to claim 26, and combining with a pharmaceutically acceptable carrier, thereby preparing an agent for the diagnosis or for the treatment or prevention of AITP.

29. A method for preparing an agent for exerting an effect on the binding of fibrinogen to blood platelets providing a polypeptide according to claim 26, and combining with a pharmaceutically acceptable carrier, thereby preparing an agent for exerting an effect on the binding of fibrinogen to blood platelets.